ArticleDiscover oncology2026
Predictors and kinetics of ATO-induced leukocytosis in acute promyelocytic leukemia patients: a retrospective study.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAlthough Arsenic trioxide (ATO) has revolutionized acute promyelocytic leukaemia (APL) from a uniformly fatal disease to one of the most curable leukemias, leukocytosis is a common life-threatening side effect and is associated with inferior results. This study aimed to describe leukocyte proliferation kinetics and explore predictors of leukocytosis among APL patients in order to guide individualized application of ATO.
resultsIn this retrospective study of 100 patients, the incidence of leukocytosis in the single drug ATO group was 74.5%, while that in the ATO- chemotherapy group was 93.9% (P = 0.018). The dynamic changes in leukocytosis showed a higher WBC count in the ATO-chemotherapy group. The median time to leukocytosis was the 9th day (IQR, 6.00-14.00). The duration of leukocytosis was shorter in the ATO single agent group. The uni-variate analysis and multi-variable analysis showed that the same independent prognostic factor was the time to double WBC for leukocytosis for all patients (OR 11.459, 95% CI, 2.121-61.897) and ATO single agent patients (OR 16.603, 95% CI, 1.635-168.635). The area under the ROC curve was 0.835 (95% CI, 0.700-0.971) for all APL patients and 0.822 (95% CI, 0.675-0.969) for single ATO-induced leukocytosis.
conclusionsThe kinetics of leukocytosis induced by single-agent ATO and ATO-chemotherapy were different. The time to double WBC≤7th day was identified as an independent poor prognostic factor for single ATO-induced leukocytosis in APL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.